A Randomized, Double-blind, Prospective Trial of Prophylactic EVOZAC® Calming Skin Spray for EGFR-TKIs Associated Rash Eruption in Non-small Cell Lung Cancer
Not suitable: no more information is needed to be described.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Lesion counts in total face at completion of the study period (week 4)
12 months
No
li zhang, MD
Principal Investigator
Sun Yat-sen University
China: Food and Drug Administration
EVOZAC20110210
NCT01528488
December 2011
March 2013
Name | Location |
---|